Program
Roflumilast
Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “ARQ-151 cream 0.05%”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.
Drug pageRoflumilast: every studyMany companies study it; this page follows only the 61 they lead. All 118 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 340 open or running | phase 4since Mar 30, 2011 | Jun 9, 2003 | none ahead |
| Arcutis Biotherapeuticsits history only | 181 open or running | phase 3since Dec 23, 2019 | Dec 29, 2017 | Apr 27, 2028phase 3 · NCT07916480 |
| Huadong Medicineits history only | 31 open or running | phase 3since Sep 30, 2024 | Sep 30, 2024 | Jun 30, 2027phase 3 · NCT07683806 |
| FLUIDDA nvits history only | 20 open or running | phase 4since Nov 21, 2011 | Nov 21, 2011 | none ahead |
| Integrative Skin Science and Researchits history only | 11 open or running | phase 4since Apr 23, 2026 | Apr 23, 2026 | Aug 2027phase 4 · NCT07560618 |
| Padagisits history only | 10 open or running | phase 3since Feb 28, 2023 | Feb 28, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 2since Jan 25, 2016 | Jan 25, 2016 | none ahead |
| Takedaits history only | 10 open or running | phase 1since Mar 4, 2014 | Mar 4, 2014 | none ahead |
Also a collaborator on its studies: Tanabe Pharma, Fougera Pharmaceuticals and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Nov 17, 2003.
- Feb 25, 2020Phase 3 study in Chronic Plaque PsoriasisArcutis Biotherapeutics · NCT04286607 · 337 enrolled · United States, Canada, Dominican Republic
- Nov 30, 2020Phase 2 study in PsoriasisArcutis Biotherapeutics · NCT04655313 · 20 enrolled · United States, Canada, Dominican Republic
- Feb 5, 2021Phase 2 study in PsoriasisArcutis Biotherapeutics · NCT04746911 · 10 enrolled · United States, Canada, Dominican Republic
- Feb 24, 20212 phase 3 studies in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04773600, NCT04773587
- Mar 16, 2021Phase 3 study in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04804605 · 1,220 enrolled · United States, Canada
- Apr 11, 2021Phase 3 study in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04845620 · 652 enrolled · United States, Canada
- Aug 25, 2021Phase 3 study in Scalp PsoriasisArcutis Biotherapeutics · NCT05028582 · 432 enrolled · United States, Canada
- Feb 28, 2023Padagis’s first study: phase 3 study in Plaque PsoriasisNew to PadagisPadagis · NCT05763082 · 416 enrolled · United States
- Sep 30, 2024Huadong Medicine’s first study: phase 3 study in Dermatitis, AtopicNew to Huadong MedicineHuadong Medicine · NCT06631170 · 354 enrolled · China
- Oct 9, 2024Phase 3 study in Plaque PsoriasisHuadong Medicine · NCT06648772 · 190 enrolled · China
- May 5, 2025Phase 2 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT06998056 · 101 enrolled · United States, Canada, Dominican Republic
- Apr 23, 2026Integrative Skin Science and Research’s first study: phase 4 study in Dermatitis, AtopicNew to Integrative Skin Science and ResearchIntegrative Skin Science and Research · NCT07560618 · 40 planned · United States
- Jun 22, 2026Phase 3 study in Dermatitis, SeborrheicHuadong Medicine · NCT07683806 · 309 planned · China
- Oct 30, 2026Phase 3 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT07916480 · 415 planned · United States
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Dermatitis, SeborrheicHuadong Medicine · NCT07683806
- Aug 2027Primary completion: phase 4 study in Dermatitis, AtopicIntegrative Skin Science and Research · NCT07560618
- Apr 27, 2028Primary completion: phase 3 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT07916480
TargetBeta
“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 5 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ensifentrinerule | Merck | phase 3 | 17 |
Studies
The newest 60 of 61 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07916480Dermatitis, Atopic · United States | 3 | Recruiting | Arcutis Biotherapeutics | Apr 27, 2028 | 415 |
| NCT07683806Dermatitis, Seborrheic · China | 3 | Recruiting | Huadong Medicine | Jun 30, 2027 | 309 |
| NCT07560618Dermatitis, Atopic · United States | 4 | Recruiting | Integrative Skin Science and Research | Aug 2027 | 40 |
| NCT06998056Dermatitis, Atopic · United States, Canada, Dominican Republic | 2 | Completed | Arcutis Biotherapeutics | Dec 4, 2025 | 101 |
| NCT06648772Plaque Psoriasis · China | 3 | Completed | Huadong Medicine | Oct 13, 2025 | 190 |
| NCT06631170Dermatitis, Atopic · China | 3 | Completed | Huadong Medicine | May 27, 2025 | 354 |
| NCT05763082Plaque Psoriasis · United States | 3 | Completed | Padagis | Aug 8, 2023 | 416 |
| NCT05028582Scalp Psoriasis · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Jun 3, 2022 | 432 |
| NCT04845620Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Jun 1, 2023 | 652 |
| NCT04804605Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | May 28, 2024 | 1,220 |
| NCT04773600Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Sep 29, 2022 | 683 |
| NCT04773587Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Aug 30, 2022 | 654 |
| NCT04746911Psoriasis · United States, Canada, Dominican Republic | 2 | Completed | Arcutis Biotherapeutics | May 11, 2022 | 10 |
| NCT04655313Psoriasis · United States, Canada, Dominican Republic | 2 | Completed | Arcutis Biotherapeutics | Jan 12, 2022 | 20 |
| NCT04286607Chronic Plaque Psoriasis · United States, Canada, Dominican Republic | 3 | Completed | Arcutis Biotherapeutics | Jan 22, 2024 | 337 |
| NCT04279119Plaque Psoriasis · United States | 1 | Completed | Arcutis Biotherapeutics | Mar 25, 2021 | 26 |
| NCT04211389Chronic Plaque Psoriasis · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Nov 23, 2020 | 442 |
| NCT04211363Chronic Plaque Psoriasis · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Nov 16, 2020 | 439 |
| NCT04156191Dermatitis, Atopic · United States | 1 | Completed | Arcutis Biotherapeutics | May 2, 2023 | 101 |
| NCT03916081Dermatitis, Atopic · United States, Canada | 2 | Completed | Arcutis Biotherapeutics | Nov 4, 2019 | 136 |
| NCT03764475Plaque Psoriasis · United States, Canada | 2 | Completed | Arcutis Biotherapeutics | Oct 8, 2020 | 332 |
| NCT03638258Plaque Psoriasis · United States, Canada | 2 | Completed | Arcutis Biotherapeutics | May 29, 2019 | 331 |
| NCT03392168Psoriasis · United States, Canada | 2 | Completed | Arcutis Biotherapeutics | May 2, 2018 | 91 |
| NCT02671942Pulmonary Disease, Chronic Obstructive · China | 2 | Terminated | Sino Biopharmaceutical | Jun 13, 2018 | 55 |
| NCT02451540Pulmonary Disease, Chronic Obstructive · Belgium | 2 | Terminated | FLUIDDA nv | Aug 31, 2017 | 13 |
| NCT02165826Pulmonary Disease, Chronic Obstructive · Slovakia | 3 | Completed | AstraZeneca | Sep 1, 2015 | 1,323 |
| NCT02079844Schizophrenia · United Kingdom | 1 | Completed | Takeda | Jun 2015 | 20 |
| NCT02051335Memory Disorders · United Kingdom | 1 | Completed | AstraZeneca | May 2014 | 27 |
| NCT01856764Dermatitis, Atopic · Germany | 2 | Completed | AstraZeneca | Mar 2014 | 40 |
| NCT01765192Asthma · Germany, Hungary, South Africa | 2 | Completed | AstraZeneca | Oct 2013 | 64 |
| NCT01703260Nonalcoholic Steatohapatitis · United States | 2 | Terminated | AstraZeneca | Sep 2014 | 20 |
| NCT01664624Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Nov 2012 | 40 |
| NCT01509677Pulmonary Disease, Chronic Obstructive · Denmark, Germany, Poland and more | 3 | Completed | AstraZeneca | Feb 1, 2016 | 158 |
| NCT01480661Pulmonary Disease, Chronic Obstructive · Belgium | 4 | Completed | FLUIDDA nv | Apr 2013 | 41 |
| NCT01473758Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Terminated | AstraZeneca | Mar 2014 | 81 |
| NCT01443845Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more | 4 | Completed | AstraZeneca | Nov 30, 2015 | 2,354 |
| NCT01365533Allergic Asthma · Canada | 2 | Completed | AstraZeneca | Jul 2005 | 48 |
| NCT01354782Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | AstraZeneca | Jun 2011 | 32 |
| NCT01329029Pulmonary Disease, Chronic Obstructive · Australia, Austria, Belgium and more | 4 | Completed | AstraZeneca | Mar 2014 | 1,945 |
| NCT01313494Pulmonary Disease, Chronic Obstructive · China, Hong Kong, Singapore | 3 | Completed | AstraZeneca | May 2012 | 626 |
| NCT01140542Diabetes Mellitus, Type 2 | 2 | Completed | AstraZeneca | Nov 2007 | 487 |
| NCT00940329Healthy · Germany | 1 | Completed | AstraZeneca | Jul 2004 | 27 |
| NCT00746434Plaque Psoriasis | 2 | Withdrawn | AstraZeneca | Jun 2009 | 0 |
| NCT00746382Dermatitis | 2 | Withdrawn | AstraZeneca | Jun 2009 | 0 |
| NCT00430729Pulmonary Disease, Chronic Obstructive · Australia, Austria, Canada and more | 3 | Completed | AstraZeneca | 1,100 | |
| NCT00424268Pulmonary Disease, Chronic Obstructive · Austria, France, Germany and more | 3 | Completed | AstraZeneca | Jan 2008 | 743 |
| NCT00313209Pulmonary Disease, Chronic Obstructive · Austria, Belgium, Canada and more | 3 | Completed | AstraZeneca | Jul 2007 | 933 |
| NCT00297115Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more | 3 | Completed | AstraZeneca | Apr 2008 | 1,568 |
| NCT00297102Pulmonary Disease, Chronic Obstructive · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | Jul 2008 | 1,523 |
| NCT00246935Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | AstraZeneca | Jan 2007 | 150 |
| NCT00246922Asthma · Japan | 3 | Completed | AstraZeneca | Jan 1, 2007 | 150 |
| NCT00242320Pulmonary Disease, Chronic Obstructive · Hong Kong, Korea, Republic of, Malaysia and more | 3 | Completed | AstraZeneca | May 2007 | 551 |
| NCT00242307Asthma · Japan | 3 | Completed | AstraZeneca | Sep 1, 2006 | 450 |
| NCT00242294Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | AstraZeneca | Sep 2006 | 570 |
| NCT00163527Asthma · United States, Austria, Croatia and more | 3 | Completed | AstraZeneca | Nov 2005 | 2,054 |
| NCT00163475Asthma · Australia, Belgium, France and more | 3 | Completed | AstraZeneca | Aug 2005 | 511 |
| NCT00108823Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more | 3 | Completed | AstraZeneca | 550 | |
| NCT00076089Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more | 3 | Completed | AstraZeneca | Dec 2005 | 1,100 |
| NCT00076076Asthma · United States, Russian Federation, Ukraine | 3 | Completed | AstraZeneca | 822 | |
| NCT00073177Asthma · United States, Argentina, Colombia and more | 3 | Completed | AstraZeneca | 819 |
How it is read
Names in the registry
- “Roflumilast”, 37 entries
- “Roflumilast Cream 0.15%”, 5 entries
- “Roflumilast Cream 0.3%”, 3 entries
- “ARQ-151 cream 0.05%”, 2 entries
- “Roflumilast Foam 0.3%”, 2 entries
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 21 studies
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Asthma, 8 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.